
Red yeast rice supplements have already been restricted in the EU, and the Commission has been preparing a further step that would prohibit monacolins in[…]

The EU joint clinical assessment is no longer only about medicines. Procedural rules for medical devices and in vitro diagnostics are now in place, and[…]

Once the dossier is in, the developer role in a joint clinical assessment narrows sharply. Knowing the few points where you can act, and the[…]

In the EU joint clinical assessment, the questions your dossier must answer are set through a scoping exercise in which the developer has very limited[…]

Under the MDR, an importer or distributor is not a passive link in the supply chain. Each has its own verification duties, and each can[…]

Hospitals, laboratories and specialist manufacturers sometimes assume that a device made for a single patient or a single institution sits outside the regulations. In fact[…]

Post-market clinical follow-up is where the clinical evaluation of a device is kept honest. Under the MDR it is a continuous process, not a one-off[…]

Regulation (EU) 2023/607 gave many devices certified under the old directives extra time to move to the MDR, but the extension is conditional. A device[…]

Routine pharmacovigilance is not always enough to keep an important risk under control. When it is not, additional risk minimisation measures come into play, and[…]

A conditional marketing authorisation lets the EU approve a medicine on less complete data than normal, where patients have an unmet need and the benefit[…]